Liquidia Sinks 5% After Recent Rally
Liquidia shares held steady in early Tuesday trading after dropping 5% Monday to $58.75. The company reported Q1 YUTREPIA net sales of $129.9 million and over 4,500 prescriptions since its June 2025 launch. CEO Roger Jeffs and CFO Michael Kaseta will give a business update at the Jefferies Global Healthcare Conference on Wednesday. Legal risks remain as United Therapeutics seeks to block YUTREPIA sales.
